GBA Presents: RADIO SAVANT-!

Discussion in 'Stocks' started by stonedinvestor, May 13, 2022.

  1. #16941     Apr 30, 2023
  2. We have our PureCycle Save the world play and we have PYPL as our big two new buys.

    Why do I also want to buy down & ugly AFRM-?

    Quite simply I think AFRM well situated in the space is about as ripe a take out stock as I can find. In fact I could see Paypal buying AFRM (Or Klarna) ///

    ADD AFRM to Watch<-------
     
    #16943     Apr 30, 2023

  3. <<<THE GBA WATCH LIST>>>

    1->Viking Therapeutics, Inc. (VKTX)
    20.92+1.31 (+6.65%)

    2->Stride, Inc. (LRN)

    3--> AFRM

    4--> QURE-- I HAVE TO DO MY DD STILL!

    (5--> RAIN)-- We should get our read out within 2 weeks here// I'm well down on the name
    and even worse have hooked a bunch of big wigs into the action. They are all going to hate me unless I can pull a rabbit from the hat here.
     
    #16944     Apr 30, 2023
  4. Holy Crap!
     
    #16945     Apr 30, 2023
  5. they are coming!
     
    #16946     Apr 30, 2023
  6. Van how cheap am I. Or how afraid of change?<---------

    The Dryer. I find I can dry successfully small loads with no towels. When It's a full load
    with wet towels it shrieks and makes a horrible wail that cause my wife to scream at me-- GET A NEW ONE!

    ... Then I secretly hang the towels in the bathroom and do the dryer in mini loads....
     
    #16947     Apr 30, 2023
  7. I have had my share of bad luck with eye based biotechs. It's a tricky sector within a sector.

    Part of the problem is the hype, these stocks are going after a very large market... in fact most all old people have some dry eye problem. Or worse, I'm afraid to get my checkup for just this reason....

    Here is a bio in phase 1 that has a 10 month and counting positive read out--
    Ocular Therapeutix initiated with Outperform, $18 target at Baird 04/21 OCUL Baird analyst Colleen Kusy last night initiated coverage of Ocular Therapeutix with an Outperform rating and $18 price target. Ocular's OTX-TKI has shown "robust" Phase 1 data in reducing the treatment burden and keeping a high percentage of wet age-related macular degeneration patients VEGF-free at 10 months, the analyst tells investors in a research note. The firm believes OTX-TKI could offer a meaningfully longer treatment interval and take share in wet AMD, a "massive market." It also sees "strong rationale" in diabetic retinopathy, another potentially multi-billion-dollar market.

    2 potential multi - billion markets?
     
    #16948     Apr 30, 2023
  8. Amazon omits any reference to India in Q1 report, call, TC reports 14:47 AMZN Amazon omitted any reference to its business in India in this week's earnings call and report, a notable shift for the company that has consistently highlighted growth and a bullish outlook in the South Asian country, TechCrunch's Manish Singh reports. The lack of information on India in the Q1 report and call, the first since early 2014, follows the e-commerce giant's shutdown of multiple services in the country, including food delivery and wholesale distribution, the author says.
     
    #16949     Apr 30, 2023
  9. [​IMG]
     
    #16950     Apr 30, 2023